Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

Summary

Entera Bio has reached an FDA agreement to initiate Phase 3 development of EB613, an oral osteoporosis drug. The company is preparing to begin Phase 3 clinical trials following the regulatory meeting.